We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The lawsuit sought to hold the drugmakers liable under the state’s Drug Dealer Liability Act (DDLA), which allows parents, employers, insurers and government entities to sue “persons in the community who have joined the illegal drug market.” Read More
The FDA denied a request by Canadian drugmaker Apotex to rescind its approval of a competing ANDA for a potassium chloride oral solution submitted by Novel Laboratories — granted on the same day Apotex qualified for 180-day competitive generic therapy (CGT) exclusivity. Read More
On the heels of CMS’ proposed rule to require disclosure of drug prices in TV ads, the FDA issued draft guidance Tuesday on presenting efficacy and risk information in direct-to-consumer (DTC) promotional materials and drug ads. Read More
“Each CDM system represents a trade off on where to set the balance between the efforts invested in data management and data analysis. Where the emphasis is placed is likely to have an impact on the speed of studies,” the EMA said. Read More
“In too many cases, there is no generic competition for these costly branded drugs even after they have lost their exclusivity protections,” said FDA Commissioner Scott Gottlieb. Read More
The FDA released draft guidance Monday on how sponsors of treatments of rare diseases can get more from their pre-investigational new drug meetings with the agency. Read More
The FDA might be willing to extrapolate clinical data for targeted therapies even if sponsors can’t recruit patients with a specific genetic variant of the disease being treated, the agency says in the first of two guidance documents issued Monday. Read More